Trial Profile
A Randomized, Cross-over Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986177 (an Oral Antithrombotic) With Single and Dual Antiplatelet Therapy (Aspirin and Clopidogrel) in Healthy Participants
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Oct 2022
Price :
$35
*
At a glance
- Drugs Aspirin (Primary) ; Clopidogrel (Primary) ; Milvexian (Primary)
- Indications Thrombosis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 29 Aug 2022 Results presented at the ESC Congress 2022 - Annual Congress of the European Society of Cardiology
- 23 Jul 2019 Status changed from recruiting to completed.
- 14 Jan 2019 Planned End Date changed from 18 Jan 2019 to 2 Feb 2019.